Videos

In this Lungcast episode, Mora and Sadeameli highlight Asthma Action Plans as well as Asthma Peak Weak considerations for children in the new school year.

Yosipovitch spoke in this interview about the clinical trials leading up to the FDA approval of his nemolizumab for patients with prurigo nodularis.

In this interview, Yosipovitch discusses his team’s findings on nemolizumab and the significance of the drug’s FDA approval for those with prurigo nodularis.

Deepak Bhatt, MD, MPH, MBA, discusses 7 trials to watch from hotline or late-breaking sessions at the upcoming European Society of Cardiology Congress 2024.

In this interview, Kim speaks about the significance of the FDA approval of neffy for patients who face the threat of anaphylaxis and other severe allergic reactions.

In this interview, Chovatiya spoke with the editorial team about the global prevalence findings on patients with seborrheic dermatitis and their implications.

In this video series segment, Casey Paleos, MD, provides insight into what he considers to be the most pertinent unanswered questions surrounding MDMA-assisted therapy in PTSD.

In this video series segment, Casey Paleos, MD, discusses his outlook on the potential of psychedelic therapies in PTSD looking forward.

In this video series segment, Casey Paleos, MD, offers insight into the impact of historic stigma associated with psychedelic therapies on acceptance in psychiatric care.

In this video series segment, Casey Paleos, MD, provides perspective on the current options and unmet needs in the management of posttraumatic stress disorder.

Brett King, MD, PhD, discusses the LEVEL UP trial and how it represents the field of dermatology's desire to advance care and advocate for new standards of care.

This segment of the latest Lungcast featured a discussion about heat and its interplay with various types of common medications.

This interview segment featured Silverberg discussing the AHEAD atopic dermatitis recommendations and their implications for clinicians and patients.

Silverberg discusses the new AHEAD recommendations for optimizing atopic dermatitis management, highlighting goals, disease severity assessments, and guidance for escalation.

In this Lungcast segment, Bludorn speaks on commonly-seen heat-related illnesses amid a changing climate as well as how to screen for related risks.

In this interview, Gooderham highlights the ARRECTOR study findings which led to roflumilast foam’s supplemental new drug application to the FDA.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 key interviews from the American Society of Retina Specialists (ASRS) 42nd Annual Meeting.

Pre-dose IOP outcomes in eyes with DME receiving aflibercept 8 mg or 2 mg were comparable through Week 48 of the Phase 2/3 PHOTON trial.

A post hoc analysis of PHOTON showed the utility of aflibercept 8 mg in patients with DME, irrespective of baseline visual acuity.

In this episode of Crisis Point, 3 experts in dermatology discuss ways in which those in the field are working to improve visibility of diverse skin types within dermatology education.

A recap of the 5 most popular topics related to gene therapy in ophthalmology coming from the 42nd American Society of Retina Specialists meeting.

Brett King, MD, PhD, discusses how the deuruxolitinib approval impacts the treatment landscape of alopecia areata.

In this part of our 5-part series, Gus Alva, MD discusses the next steps in research for long-term effects and broader applications of MDMA-assisted therapy.

In this part of our 5-part series, Gus Alva, MD explores MDMA’s neurochemical impact and the need for ongoing research.

In this part of our 5-part series, Gus Alva, MD highlights the importance of education and overcoming skepticism about MDMA-assisted therapy.

In this part of our 5-part series, Gus Alva, MD talks about MDMA's efficacy in controlled settings and addresses misconceptions.

Presented at ASRS 2024, late-breaking RHONE-X data shows more than 90% of patients experienced the absence of DME after four years of faricimab.

Eyes with GA that developed MNV in the GATHER trials experienced a slower growth rate with avaincaptad pegol than with sham treatment.